Americas to Command Largest Share in Hemoglobinopathies Market

Hemoglobinopathies Market Overview:

The global Hemoglobinopathies Market size is anticipated to grow at a 10.2% CAGR between 2019-2025, states the latest Market Research Future (MRFR) report. Hemoglobinopathy, simply put, is a blood disorder that is inherited in which a person has a form of hemoglobin that is abnormal, or there is a decreased hemoglobin production (thalassemia). This is basically a genetic defect that leads to the abnormal structure of a globin chain of the hemoglobin molecule. Hb E, Hb C, thalassemia, and sickle cell anemia are the different forms of hemoglobin disorders. 

Numerous factors are pushing the growth of the global hemoglobinopathies market. Such factors, according to the new Market Research Future report, include increasing prevalence of blood cancer cases, favorable reimbursement scenario both for diagnostic tests as well as treatment, and innovative approaches such as genetic testing. Additional factors pushing the growth of the hemoglobinopathies market include increasing company and government initiatives to spread awareness about hemoglobin variant diseases, and rising incidence of hemoglobin disorders such as Hb E, Hb C, thalassemia, and sickle cell anemia. 

On the contrary, accessibility of diagnostic alternatives of hemoglobinopathies, lack of awareness about diagnoses, and lack of treatment are factors that may hamper the hemoglobinopathies market growth during the forecast period. 

Key Players:
·         Invenux
·         HemaQuest Pharmaceutical
·         Mast Therapeutics
·         Acceleron Pharma
·         Gamida Cell
·         Alnylam Pharmaceuticals
·         Celgene Corporation
·         Prolong Pharmaceuticals
·         Emmaus Life Sciences Inc
·         Bluebird Bio Inc
·         Global Blood Therapeutics

Market Segmentation:

·         The Market Research Future report offers a complete segmental analysis of the global hemoglobinopathies market based on test types, treatment, and type. 

·         By type, the global hemoglobinopathies market is segmented into sickle cell disease, thalassemia, and other Hb variant diseases. The thalassemia segment is again segmented into beta thalassemia and alpha thalassemia.

·         By treatment, the global hemoglobinopathies market is segmented into hydroxyurea, ACE inhibitors, antibiotics, analgesics, blood transfusions, and stem-cell transplantation.

·         By end user, the global hemoglobinopathies market is segmented into diagnostics laboratories, hospitals and clinics, and others. 

Regional Analysis:

By region, the global hemoglobinopathies market report covers the latest trends and growth opportunities across North America, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will command the largest share in the market during the forecast period as a major part of the populace suffer from sickle cell disease, a common inherited blood disorder. Moreover, the presence of superior-quality healthcare infrastructure, better reimbursement scenario, and increasing investments made by the key players in the research and development activities. 

The global hemoglobinopathies market in Europe will hold the second-largest share in the market over the forecast period and will be succeeded by the APAC region that is predicted to grow at the fastest pace during the forecast period. Numerous factors are propelling the growth of hemoglobinopathies market in the region such as increasing incidence of such disorders in the region including Hb E, Hb C, thalassemia, and sickle cell anemia, increasing patient awareness level, and availability of low-cost, indigenously-manufactured diagnostic kits to treat sickle cell disease and thalassemia. 

The global hemoglobinopathies market in the MEA will have a small share in the market during the forecast period for low economic development, particularly in the African region.

Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more